Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma |
Jun, Baek Gyu
(Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine)
Kim, Young Don (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) Cheon, Gab Jin (Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine) Kim, Eun Seog (Department of Radiation Oncology, Soonchunhyang University Cheonan Hospital) Jwa, Eunjin (Department of Radiation Oncology, Soonchunhyang University Cheonan Hospital) Kim, Sang Gyune (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) Kim, Young Seok (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) Kim, Boo Sung (Department of Internal Medicine, Soonchunhyang University Bucheon Hospital) Jeong, Soung Won (Department of Internal Medicine, Soonchunhyang University Seoul Hospital) Jang, Jae Young (Department of Internal Medicine, Soonchunhyang University Seoul Hospital) Lee, Sae Hwan (Department of Internal Medicine, Soonchunhyang University Cheonan Hospital) Kim, Hong Soo (Department of Internal Medicine, Soonchunhyang University Cheonan Hospital) |
1 | Sheu JC, Huang GT, Chen DS, et al. Small hepatocellular carcinoma: intratumor ethanol treatment using new needle and guidance systems. Radiology 1987;163:43-48. DOI |
2 | Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer 1991;68:2150-2154. DOI |
3 | Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-1248. DOI |
4 | Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810-821. DOI |
5 | Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006;65:426-434. DOI |
6 | Yoon SM, Lim YS, Park MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One 2013;8:e79854. DOI |
7 | Jung J, Yoon SM, Kim SY, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 2013;8:249. DOI |
8 | Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys 2015;91:986-994. DOI |
9 | Sanuki N, Takeda A, Oku Y, et al. Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res 2015;45:540-547. DOI |
10 | Song JH, Son SH, Kay CS, Jang HS. Identification of biologically effective dose-volumetric parameters that predict radiation-induced hepatic toxicity in patients treated with helical tomotherapy for unresectable locally advanced hepatocellular carcinoma. Medicine (Baltimore) 2015;94:e1904. DOI |
11 | Son SH, Choi BO, Ryu MR, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 2010;78:1073-1080. DOI |
12 | Liang SX, Huang XB, Zhu XD, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol 2011;98:265-269. DOI |
13 | Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004;60:1502-1509. DOI |
14 | Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-225. DOI |
15 | Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-S100. DOI |
16 | Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531. DOI |
17 | Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011;21:256-263. DOI |
18 | Okajima C, Arii S, Tanaka S, et al. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg 2015;209:199-205. DOI |
19 | Scorsetti M, Comito T, Cozzi L, et al. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol 2015;141:1301-1309. DOI |
20 | Mendez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006;45:831-837. DOI |
21 | Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1756-1761. DOI |
22 | Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol 2015;115:211-216. DOI |
23 | Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-e453. DOI |
24 | Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664. DOI |
25 | Ikai I, Kudo M, Arii S, et al. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010;40:1043-1059. DOI |
26 | Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-231. DOI |
27 | Son SH, Jang HS, Jo IY, et al. Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma. Radiat Oncol 2014;9:101. DOI |
28 | Culleton S, Jiang H, Haddad CR, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-417. DOI |
29 | Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917. DOI |
![]() |